SaNOtize is a global, clinical-stage pharmaceutical company based in Vancouver, Canada. Its patented technologies deliver the natural antimicrobial properties of nitric oxide (NO) to treat a wide range of common viral, bacterial, and fungal infections.
SaNOtize was co-founded in 2017 by Gilly Regev, PhD, a biochemist by training, and Chris Miller, PhD, a longtime leader in the NO field. Together the team pioneered a novel delivery system for NO, enabling it to be used for the first time as a topical antimicrobial.
The company’s lead therapy is a NO-based nasal spray, NONS™, shown to be effective against viruses including COVID-19 and registered or approved in more than 10 countries worldwide. Its groundbreaking approval in India marked the first-ever regulatory drug approval of NO to treat an infection. Other pipeline products include treatments for chronic sinusitis, diabetic foot ulcers, and warts.